Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 1/20 | 0.70 |
| ▸ | HDAC1 | Q13547 | 12/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.44 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL403079 | 1.00 | SMO (0.70) | SMOHDAC1MAPTKCNH2MCHR1 | |
| SCHEMBL404107 | 1.00 | SMO (0.70) | SMOHDAC1MAPTKCNH2MCHR1 | |
| SCHEMBL402178 | 0.92 | SMO (0.64) | SMOHDAC1MAPTHDAC2RAB9A | |
| SCHEMBL402864 | 0.92 | SMO (0.64) | SMOHDAC1MAPTHDAC2RAB9A | |
| SCHEMBL4971491 | 0.92 | HDAC1 (0.62) | SMOHDAC1MAPTKCNH2MCHR1 | |
| SCHEMBL4967912 | 0.92 | HDAC1 (0.62) | SMOHDAC1MAPTKCNH2MCHR1 | |
| SCHEMBL399419 | 0.92 | SMO (0.64) | SMOHDAC1MAPTHDAC2RAB9A | |
| SCHEMBL401222 | 0.90 | SMO (0.85) | SMOHDAC1MAPTKCNH2MCHR1 | |
| SCHEMBL401175 | 0.87 | SMO (0.61) | SMOHDAC1MAPTKCNH2HDAC2 | |
| SCHEMBL4972146 | 0.86 | SMO (0.59) | SMOHDAC1HDAC2RAB9AMAPK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957461-B1 | BISAMIDE INHIBITORS OF HEDGEHOG SIGNALING | GENENTECH INC (US) | 2016-11-02 | — | — | EP | claimed |
| US-8101610-B2 | Blocking signals; anticancer agents | GENENTECH, INC. (US) | 2012-01-24 | — | — | US | claimed |
| US-20080269215-A1 | Bisamide Inhibitors of Hedgehog Signaling | GENENTECH INC. (US) | 2008-10-30 | — | — | US | claimed |
| EP-1957461-A1 | BISAMIDE INHIBITORS OF HEDGEHOG SIGNALING | Genentech, Inc. (US) | 2008-08-20 | — | — | EP | claimed |
| WO-2007059157-A1 | BISAMIDE INHIBITORS OF HEDGEHOG SIGNALING | GENENTECH, INC. (US) | 2007-05-24 | — | — | WO | claimed |
| EP-1957461-B1 | BISAMIDE INHIBITORS OF HEDGEHOG SIGNALING | GENENTECH INC (US) | 2016-11-02 | — | — | EP | disclosed |
| US-8101610-B2 | Blocking signals; anticancer agents | GENENTECH, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101610-B2 | Blocking signals; anticancer agents | GENENTECH, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101610-B2 | Blocking signals; anticancer agents | GENENTECH, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20080269215-A1 | Bisamide Inhibitors of Hedgehog Signaling | GENENTECH INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269215-A1 | Bisamide Inhibitors of Hedgehog Signaling | GENENTECH INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269215-A1 | Bisamide Inhibitors of Hedgehog Signaling | GENENTECH INC. (US) | 2008-10-30 | — | — | US | disclosed |
| EP-1957461-A1 | BISAMIDE INHIBITORS OF HEDGEHOG SIGNALING | Genentech, Inc. (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007059157-A1 | BISAMIDE INHIBITORS OF HEDGEHOG SIGNALING | GENENTECH, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007059157-A1 | BISAMIDE INHIBITORS OF HEDGEHOG SIGNALING | GENENTECH, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269215-A1 | Bisamide Inhibitors of Hedgehog Signaling | SHH, GLI1, SMO | SMO 3/4885HDAC1 105/4885MAPT 2726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.